ArticleMolecular biology reports2026
TRIM27 enhances NF-κB/MAPK activation by ubiquitinating and degrading TRAF3 to drive asthma-induced airway inflammation.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundAsthma is a chronic inflammatory airway disease, and airway epithelial cell injury is closely associated with disease progression. TRIM27, as an E3 ubiquitin ligase, plays a significant role in immune-inflammatory responses. This study aims to investigate the role of TRIM27 in airway epithelial cell injury and inflammation.
methodsHouse dust mite extract (HDM)-induced mouse or 16HBE cell models were constructed to simulate asthma in vivo and in vitro. Lung histopathological injury was assessed via HE and PAS staining. Bronchoalveolar lavage fluid (BALF) inflammatory cell counts and ELISA were used to measure inflammation levels. Cell viability and apoptosis was detected by CCK-8, flow cytometry and TUNEL staining. RT-qPCR and Western blot were employed to detect related gene and protein expression.
resultsTRIM27 was upregulated in both in vivo and in vitro asthma models. TRIM27 knockdown alleviated HDM-induced lung histopathological damage in mice, reduced goblet cell hyperplasia and inflammatory cell infiltration, and decreased inflammatory cytokine levels. In vitro experiments showed that TRIM27 knockdown partially restored HDM-induced decline in cell viability, inhibited apoptosis, ROS generation, and inflammatory cytokine release. Mechanistic studies revealed that HDM stimulation activated the NF-κB/MAPK pathway, while TRIM27 knockdown suppressed its activation. Further research demonstrated that TRIM27 activates the NF-κB/MAPK pathway by promoting TRAF3 ubiquitination and degradation. TRAF3 knockdown can weaken the beneficial effects of TRIM27 knockdown.
conclusionTRIM27 activates the NF-κB/MAPK signaling pathway by promoting TRAF3 ubiquitination and degradation, thereby exacerbating airway epithelial cell injury and inflammatory response, and promoting asthma progression.
Indexed as
Identifiers
42909561What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.